Showing 41 - 60 results of 111 for search '(functional OR function) data analysis (fda)', query time: 0.09s Refine Results
  1. 41
  2. 42

    Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative cl... by James D Berry, Melissa Hagan, Jeffrey Zhang, Ying Liu, Malgorzata Ciepielewska

    Published 2025-01-01
    “…Background: IV edaravone is US FDA approved for the treatment of ALS and was shown in clinical trials to slow the rate of physical functional decline. …”
    Article
  3. 43

    Development and validation of an AI-enabled oral score using large-scale dental data by Sri Kalyan Yarlagadda, Navid Samavati, Mina Ghorbanifarajzadeh, Vlada Levinta, Alireza Sojoudi, Wardah Inam, Teresa A. Dolan

    Published 2025-07-01
    “…This score was developed using Overjet’s FDA-cleared AI platform, which detects dental conditions using bitewing and periapical radiographs, providing a detailed analysis of each tooth. …”
    Get full text
    Article
  4. 44
  5. 45
  6. 46
  7. 47

    Enhancing Forensic Analysis of Construction Project Delays Through Digital Interventions by Serife Ece Boyacioglu, David Greenwood, Kay Rogage, Andrew Parry

    Published 2025-07-01
    “…Project delays remain a persistent challenge in the construction industry, having significant financial implications and contributing to disputes between project participants. Forensic Delay Analysis (FDA) has emerged as a specialised function that identifies the root causes of such delays, quantifies their duration, and assigns responsibility to the appropriate parties. …”
    Get full text
    Article
  8. 48
  9. 49

    PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap

    Published 2025-08-01
    “…Recent global estimates suggest that over 220,000 bleeding episodes could be prevented annually by DDAVP in type 1 VWD and non-severe hemophilia A patients. New chemical and functional characterization studies, along with real-world clinical data, have been collected to support the development of a newly formulated intranasal DDAVP (HEM006), aimed at addressing the global shortage and restoring access to this essential therapy. …”
    Get full text
    Article
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54

    Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database by Lei Wang, Kunpeng Yang, Kunpeng Yang, Hui Zhao, Peiyun Lv, Chenglun Cai, Zhe Wang, Bao Wang, Bao Wang, Bao Wang

    Published 2025-06-01
    “…This study aims to systematically assess carboplatin-related AEs and explore demographic factors that may influence risk.MethodsA retrospective analysis was performed using data from the FDA Adverse Event Reporting System (FAERS) spanning the first quarter of 2004 to the third quarter of 2024. …”
    Get full text
    Article
  15. 55

    Cross-National Analysis of Opioid Prescribing Patterns: Enhancements and Insights from the OralOpioids R Package in Canada and the United States by Ankona Banerjee, Kenneth Nobleza, Duc T. Nguyen, Erik Stricker

    Published 2024-09-01
    “…Food and Drug Administration’s (FDA) National Drug Code (NDC) database. It includes functions such as load_Opioid_Table, which integrates country-specific data processing and Morphine Equivalent Dose (MED) calculations, providing a comprehensive dataset for analysis. …”
    Get full text
    Article
  16. 56
  17. 57

    Association between cyclin-dependent kinase 4/6 inhibitors and nephrotoxicity in patients with breast cancer: A Systematic Review and meta-analysis by Jiayong Cui, Jinquan Sun, Xueying Zhou, Yi Li, Jiuda Zhao, Guoshuang Shen

    Published 2024-12-01
    “…Subgroup analyses revealed varying risks among 4 different CDK 4/6 inhibitors. Furthermore, analysis of FDA Adverse Event Reporting System data corroborated these findings, emphasizing the occurrence of nephrotoxicity in real-world settings. …”
    Get full text
    Article
  18. 58

    Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting... by Wanming He, Lihua Tong, Yanling Yuan, Xia Yang, Wen Yang, Xingxi Pan

    Published 2025-02-01
    “…PurposeThe objective of the study is to systematically identify and evaluate the adverse drug reactions (ADRs) associated with the combination therapy of systematically and bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).Patients and methodsData were extracted from the Food and Drug Administration (FDA) Adverse Event Reporting System FDA Adverse Event Reporting System database. …”
    Get full text
    Article
  19. 59
  20. 60